155 related articles for article (PubMed ID: 1506148)
1. Phase II clinical trial of gadoteridol injection, a low-osmolal magnetic resonance imaging contrast agent.
Carvlin MJ; De Simone DN; Meeks MJ
Invest Radiol; 1992 Aug; 27 Suppl 1():S16-21. PubMed ID: 1506148
[TBL] [Abstract][Full Text] [Related]
2. Magnetic resonance evaluation of brain metastases from systemic malignances with two doses of gadobutrol 1.0 m compared with gadoteridol: a multicenter, phase ii/iii study in patients with known or suspected brain metastases.
Katakami N; Inaba Y; Sugata S; Tsurusaki M; Itoh T; Machida T; Tanaka H; Nakayama T; Morikawa T; Breuer J; Aitoku Y
Invest Radiol; 2011 Jul; 46(7):411-8. PubMed ID: 21467949
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of gadoteridol for magnetic resonance imaging of the brain and spine.
Runge VM; Bronen RA; Davis KR
Invest Radiol; 1992 Aug; 27 Suppl 1():S22-32. PubMed ID: 1506150
[TBL] [Abstract][Full Text] [Related]
4. MR evaluation of CNS tumors: dose comparison study with gadopentetate dimeglumine and gadoteridol.
Yuh WT; Fisher DJ; Engelken JD; Greene GM; Sato Y; Ryals TJ; Crain MR; Ehrhardt JC
Radiology; 1991 Aug; 180(2):485-91. PubMed ID: 2068317
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of gadoteridol for magnetic resonance imaging of extracranial head and neck pathology.
Zoarski GH; Parker JR; Lufkin RB; Harnsberger HR; Rhoda CH
Invest Radiol; 1992 Aug; 27 Suppl 1():S53-7. PubMed ID: 1506154
[TBL] [Abstract][Full Text] [Related]
6. [Brain magnetic resonance with magnetization transfer in multiple sclerosis. Lesion hyperintensity before and after intravenous gadolinium administration].
Renzetti P; Parodi RC; Losacco C; Rosso E; Arcuri T; Sardanelli F
Radiol Med; 1999 Sep; 98(3):138-43. PubMed ID: 10575442
[TBL] [Abstract][Full Text] [Related]
7. Visualization of blood-brain barrier disruption on MR images of cats with acute cerebral infarction: value of administering a high dose of contrast material.
Runge VM; Kirsch JE; Wells JW; Dunworth JN; Woolfolk CE
AJR Am J Roentgenol; 1994 Feb; 162(2):431-5. PubMed ID: 8310940
[TBL] [Abstract][Full Text] [Related]
8. Gadoteridol-enhanced MR imaging of malignant hepatic tumors: effects of triple versus standard doses on lesion-liver contrast.
Petersein J; Saini S; Mitchell DG; Davis PL; Johnson CD; Kuhlman JE; Parisky YR; Runge VM; Weinreb J; Bernardino ME
AJR Am J Roentgenol; 1995 Nov; 165(5):1157-61. PubMed ID: 7572495
[TBL] [Abstract][Full Text] [Related]
9. Phase III clinical studies with gadoteridol for the evaluation of neurologic pathology. A European perspective.
Seiderer M
Invest Radiol; 1992 Aug; 27 Suppl 1():S33-8. PubMed ID: 1506151
[TBL] [Abstract][Full Text] [Related]
10. Review of the use of high-dose gadoteridol in the magnetic resonance evaluation of central nervous system tumors.
Yuh WT; Fisher DJ; Mayr-Yuh NA; Tali ET; Nguyen HD; Gao F; Ehrhardt JC
Invest Radiol; 1992 Aug; 27 Suppl 1():S39-44. PubMed ID: 1506152
[No Abstract] [Full Text] [Related]
11. Efficacy of gadoteridol for contrast-enhanced magnetic resonance imaging in children.
Ball WS; Parker JR; Davis PC; Glasier CM; Morris MR
Invest Radiol; 1992 Aug; 27 Suppl 1():S45-52. PubMed ID: 1506153
[TBL] [Abstract][Full Text] [Related]
12. Comparison between two separate injections and a single injection of double-dose contrast medium for contrast-enhanced MR imaging of metastatic brain tumors.
Ochi T; Taoka T; Matsuda R; Sakamoto M; Akashi T; Tamamoto T; Sugimoto T; Sakaguchi H; Hasegawa M; Nakase H; Kichikawa K
Magn Reson Med Sci; 2014; 13(4):221-9. PubMed ID: 25167875
[TBL] [Abstract][Full Text] [Related]
13. Clinical safety and efficacy of gadoteridol: a study in 411 patients with suspected intracranial and spinal disease.
Runge VM; Bradley WG; Brant-Zawadzki MN; Carvlin MJ; DeSimone DN; Dean BL; Dillon WP; Drayer BP; Flanders AE; Harms SE
Radiology; 1991 Dec; 181(3):701-9. PubMed ID: 1947085
[TBL] [Abstract][Full Text] [Related]
14. Difference in enhancement between spin echo and 3-dimensional fast spoiled gradient recalled acquisition in steady state magnetic resonance imaging of brain metastasis at 3-T magnetic resonance imaging.
Furutani K; Harada M; Mawlan M; Nishitani H
J Comput Assist Tomogr; 2008; 32(2):313-9. PubMed ID: 18379324
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic behavior of gadoteridol injection.
McLachlan SJ; Eaton S; De Simone DN
Invest Radiol; 1992 Aug; 27 Suppl 1():S12-5. PubMed ID: 1506147
[TBL] [Abstract][Full Text] [Related]
16. Phase III multicenter trial of high-dose gadoteridol in MR evaluation of brain metastases.
Yuh WT; Fisher DJ; Runge VM; Atlas SW; Harms SE; Maravilla KR; Mayr NA; Mollman JE; Price AC
AJNR Am J Neuroradiol; 1994 Jun; 15(6):1037-51. PubMed ID: 8073972
[TBL] [Abstract][Full Text] [Related]
17. Gd-HP-DO3A in clinical MR imaging of the brain.
Runge VM; Gelblum DY; Pacetti ML; Carolan F; Heard G
Radiology; 1990 Nov; 177(2):393-400. PubMed ID: 2217775
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the safety and efficacy of gadoteridol injection (a low osmolal magnetic resonance contrast agent). Clinical trials report.
DeSimone D; Morris M; Rhoda C; Lucas T; Zielonka J; Olukotun A; Carvlin M
Invest Radiol; 1991 Nov; 26 Suppl 1():S212-6; discussion S232-5. PubMed ID: 1808133
[No Abstract] [Full Text] [Related]
19. Enhancement of cerebral diseases: how much contrast agent is enough? Comparison of 0.1, 0.2, and 0.3 mmol/kg gadoteridol at 0.2 T with 0.1 mmol/kg gadoteridol at 1.5 T.
Brekenfeld C; Foert E; Hundt W; Kenn W; Lodeann KP; Gehl HB
Invest Radiol; 2001 May; 36(5):266-75. PubMed ID: 11323514
[TBL] [Abstract][Full Text] [Related]
20. Contrast enhancement of the inner ear after intravenous administration of a standard or double dose of gadolinium contrast agents.
Suzuki H; Teranishi M; Sone M; Yamazaki M; Naganawa S; Nakashima T
Acta Otolaryngol; 2011 Oct; 131(10):1025-31. PubMed ID: 21732744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
